Choroidal Neovascularization, Visual Field, Visual AcuityCORFINCT03435926
OCT and Microperimetry in Patients With Active Neovascular ARMD (CORFI)
An observational study of Choroidal Neovascularization, Visual Field, Visual Acuity, run by University Hospital, Limoges at 1 site in France.
Trial summary
ARMD is the main cause of visual disability after 50 years old in France. Patients with active neovascular ARMD are treated with intravitreal injections of antiVEGF. Reinjections criteria are decrease of best corrected visual acuity or active neovascularization's signs (mostly found on macular OCT but also on… Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Choroidal Neovascularization, Visual Field, Visual Acuity
- How many people
- 0 participants
- Where
- 1 siteFrance
- Study dates
- 13 Feb 2018to 22 Jan 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with active neovascular ARMD treated with antiVEGF
Who may be able to join
- patients > 50 years old,
- With neovascular ARMD
- who need an induction treatment (de novo patients or patients who had their last intravitreal injection of antiVEGF more than 6 months ago)
Who cannot join
- Other maculopathies
- Severe glaucoma with central visual field defect
- Diabetic patients
- Corneal, lens or vitreous opacities interfering in OCT analysis
- Attention or comprehension deficit
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluating the Link Between Active Neovascularization Found on OCT and Eye Fixation Quality Measured With Microperimetry in ARMD Patients Treated With antiVEGF
ARMD is the main cause of visual disability after 50 years old in France. Patients with active neovascular ARMD are treated with intravitreal injections of antiVEGF. Reinjections criteria are decrease of best corrected visual acuity or active neovascularization's signs (mostly found on macular OCT but also on angiography when necessary).
The aim of this study is to evaluate the link between active neovascularization found on OCT and eye fixation quality measured with microperimetry in ARMD patients treated with antiVEGF.
Read more
Quality of eye fixation and exudative signs presents or not present on OCT will be gathered at each consultation over the two-years follow-up for each patient. The mean central retinal sensitivity, the best corrected visual acuity and the bivariate contour ellipse area will also be gathered.
In case no link will be found, for instance bad fixation quality without exudative signs on OCT or good fixation stability despite exudative signs on OCT, microperimetry should have an interest to improve reinjections criteria with a treatment more suitable to the patient.
- Medical subject headings
- Choroidal Neovascularization
What is being measured
The primary outcome is the main question the study is designed to answer.
fixation stability measured by microperimetry and exudative signs on OCT
quality of eye fixation and exudative signs presents or not present on OCT will be gathered at each consultation over the two-years follow-up.
The fixation stability is classified as follows:
- Stable if more than 75% of the fixation points are contained inside the circle of 2 degrees of diameter
- Relatively unstable if more than 75% of the fixation points are contained within the circle of 4 degrees of diameter and less than 75% contained within that of 2 degrees of diameter
- Unstable if less than 75% of the fixation points are contained within the circle of 4 degrees of diameter
Measured: 2 years
Secondary outcomes (3)
Bivariate Contour Ellipse Area (BCEA) value
BCEA will be gathered at each consultation over the two-years follow-up
Measured: 2 years
mean central retinal sensitivity
mean central retinal sensitivity will be gathered at each consultation over the two-years follow-up
Measured: 2 years
Best Corrected Visual Acuity (BCVA)
BCVA will be gathered at each consultation over the two-years follow-up
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2018
- Study start13 Feb 2018
- Primary completion22 Jan 2019
- Study completion22 Jan 2019
Why it stopped: No inclusion
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Choroidal Neovascularization, Visual Field, Visual AcuityStudies of the same condition, open and under way.
- More trials run by University Hospital, LimogesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Limoges
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03435926
- Sponsor's protocol ID
- I16021 (CORFI)
- Acronym
- CORFI
- Status last verified
- Sep 2018
- First submitted
- 7 Feb 2018
- Last updated
- 26 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Link Between Active Neovascularization Found on OCT and Eye Fixation Quality Measured With Microperimetry in ARMD Patients Treated With antiVEGF
- ClinicalTrials.gov ID
- NCT03435926
- Acronym / sponsor ID
- CORFI / I16021 (CORFI)
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: No inclusion
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University Hospital, LimogesUniversity, hospital or other
- Study start
- 13 Feb 2018 (actual)
- Primary completion
- 22 Jan 2019 (actual)
- Study completion
- 22 Jan 2019 (actual)
- First posted
- 19 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ARMD is the main cause of visual disability after 50 years old in France. Patients with active neovascular ARMD are treated with intravitreal injections of antiVEGF. Reinjections criteria are decrease of best corrected visual acuity or active neovascularization's signs (mostly found on macular OCT but also on angiography when necessary).
The aim of this study is to evaluate the link between active neovascularization found on OCT and eye fixation quality measured with microperimetry in ARMD patients treated with antiVEGF.
Quality of eye fixation and exudative signs presents or not present on OCT will be gathered at each consultation over the two-years follow-up for each patient. The mean central retinal sensitivity, the best corrected visual acuity and the bivariate contour ellipse area will also be gathered.
In case no link will be found, for instance bad fixation quality without exudative signs on OCT or good fixation stability despite exudative signs on OCT, microperimetry should have an interest to improve reinjections criteria with a treatment more suitable to the patient.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with active neovascular ARMD treated with antiVEGF
Key inclusion criteria (3 listed)
- patients > 50 years old,
- With neovascular ARMD
- who need an induction treatment (de novo patients or patients who had their last intravitreal injection of antiVEGF more than 6 months ago)
Key exclusion criteria (5 listed)
- Other maculopathies
- Severe glaucoma with central visual field defect
- Diabetic patients
- Corneal, lens or vitreous opacities interfering in OCT analysis
- Attention or comprehension deficit
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
fixation stability measured by microperimetry and exudative signs on OCT
Time frame: 2 years
quality of eye fixation and exudative signs presents or not present on OCT will be gathered at each consultation over the two-years follow-up. The fixation stability is classified as follows: * Stable if more than 75% of the fixation points are contained inside the circle of 2 degrees of diameter * Relatively unstable if more than 75% of the fixation points are contained within the circle of 4 degrees of diameter and less than 75% contained within that of 2 degrees of diameter * Unstable if less than 75% of the fixation points are contained within the circle of 4 degrees of diameter
3 secondary outcomes
Bivariate Contour Ellipse Area (BCEA) value
Time frame: 2 years
mean central retinal sensitivity
Time frame: 2 years
Best Corrected Visual Acuity (BCVA)
Time frame: 2 years
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Choroidal Neovascularization, Visual Field, Visual Acuity, run by University Hospital, Limoges at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
fixation stability measured by microperimetry and exudative signs on OCT (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.